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Background:The double-blindphase of the EARLY study of bosentan remains the only randomized controlled trial
of a PAH-targeted therapy in World Health Organization functional class (FC) II patients. We report on the efﬁ-
cacy, safety, diseaseworsening, survival and prognostic factors inmildly symptomatic pulmonary arterial hyper-
tension (PAH) patients treated with bosentan in the open-label extension phase of the EARLY study.
Methods: Exploratory efﬁcacy outcomes included 6-minute walk distance (6MWD) andWHO FC. Adverse events
were recorded. Kaplan–Meier analysis was used to estimate time to ﬁrst PAH worsening event (death, initiation
of intravenous or subcutaneous prostanoids, atrial septostomy or lung transplantation) and survival. Cox regres-
sion analysis determined factors prognostic of survival.
Results:Median exposure to bosentan (n = 173) was 51 months. At the end of the bosentan-treatment assess-
ment period, 77.8% of patients were inWHO FC I/II. Adverse events led to discontinuation of bosentan in 20.2% of
patients. Aminotransferase elevations N3× upper limit of normal occurred in 16.8%. Four-year PAH-event-free
survival and survival were 79.5% (95% conﬁdence intervals [95% CI] 73.4, 85.6) and 84.8% [95% CI 79.4, 90.2],
respectively. Low6MWD, lowmixed venous oxygenation, highN-terminal pro hormone of brain natriuretic pep-
tide levels and PAH associated with connective tissue disease were associated with a higher risk of death.
Conclusions: The majority of patients exposed to long-term bosentan maintained or improved their functional
class. Approximately 20% of the patients discontinued treatment because of adverse events, which were most
commonly PAH worsening and elevated liver enzymes.© 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Pulmonary arterial hypertension (PAH) is characterized by remodel-
ing of the pulmonary vasculature [1]. Progressive vasculopathy results
in an increase in pulmonary arterial pressure (PAP) and pulmonarye du Général Leclerc, 94270 Le
x: +33 1 45 21 79 71.
r (G. Simonneau).
eliability and freedom from bias
land Ltd. Open access under CC BY-NCvascular resistance (PVR), ultimately leading to right heart failure and
death [2].
The World Health Organization functional class (WHO FC) system
comprises four classes (I–IV), and characterizes patientswith PAHby in-
creasing functional compromise with symptoms such as dyspnea, fa-
tigue, chest pain, and syncope initially on exertion and subsequently
at rest. At the time of diagnosis, approximately 75% of patients are in
WHO FC III/IV [3]. Functional class at the time of diagnosis as well as
during follow-up is of pivotal prognostic importance [4]. Patients
starting therapy in WHO FC I/II have a better prognosis than those in
WHO FC III/IV [5] and patients who achieveWHO FC I/II after treatment
have a better prognosis than those who remain in WHO FC III/IV [6,7].
Despite a relatively well preserved exercise capacity and mild symp-
toms, patients inWHOFC II are already hemodynamically compromised-ND license. 
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better is a logical treatment strategy.
To date, EARLY (Endothelin Antagonist tRial in miLdlY symptomatic
PAH patients) remains the only prospective, randomized, placebo-
controlled, clinical trial of a PAH-targeted therapy in an exclusively
WHO FC II PAH patient population. This multicenter study randomized
185 patients from 21 countries to receive bosentan or placebo over a
6-month double-blind treatment period. Bosentan signiﬁcantly reduced
PVR in comparisonwith placebo (−22.6%, p b 0.0001) and signiﬁcantly
delayed time to PAH worsening (hazard ratio 0.227, p = 0.0114) [8].
EARLY included an open-label extension (OLE) phase to provide contin-
ued treatment for thosewhowere eligible and to collect long-term safe-
ty data on bosentan-treated patients. This article presents the ﬁnal
results of the EARLY study of bosentan in WHO FC II PAH patients;
data from the OLE phase and long-term follow-up are reported. In addi-
tion, the collection of follow-up data for all randomized patients also
provided a unique opportunity to investigate the effect of a PAH-
targeted therapy on PAH worsening, survival and factors inﬂuencing
survival.
2. Methods
2.1. Patients
Inclusion and exclusion criteria for WHO FC II PAH patients who entered the double-
blind phase of EARLY have been described previously [8]. The etiologies of PAH enrolled
into the EARLY study were idiopathic PAH (iPAH), heritable PAH, or PAH associated
with human immunodeﬁciency virus (HIV) infection, anorexigen use, congenital heart
disease (PAH-CHD; atrial septal defect of less than 2 cm in diameter, ventricular septal de-
fect of less than 1 cm in diameter, patent ductus arteriosus), connective tissue disease
(PAH-CTD) or auto-immune diseases. The study protocol conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki as reﬂected in a priori approval by each institu-
tions human research committee. Written informed consent was obtained from each
patient for entry into the double-blind phase and again for continuation into the OLE
phase.
2.2. Study design
The EARLY study was a Phase IIIb, multicenter, clinical trial of bosentan in mildly
symptomatic PAH which comprised a 6-month, double-blind, randomized, placebo-
controlled phase, an open-label, single-arm extension phase and long-term follow-up of
all randomized patients. The EARLY study was initiated in September 2004 and its OLE
was completed in February 2011 when ≥50% of the patients had had the opportunity to
be exposed to bosentan for ≥5 years (end of study). The design of the double-blind, ran-
domized phase of EARLY has been described previously [8]. In brief, after screening, eligi-
ble patients were stratiﬁed according to sildenaﬁl use and randomized 1:1 to bosentan
62.5 mg twice daily for the ﬁrst month followed by up-titration to the target dose of
125 mg twice daily thereafter (or remained at 62.5 mg twice daily if body weight was
b40 kg), or matching placebo for 6 months. The stratiﬁcation of patients on sildenaﬁl
was included in an amendment to the protocol to reﬂect a change in clinical practice
and was not intended for the purpose of assessing a combination treatment approach. Pa-
tientswho completed the 6-month double-blind phase of EARLY, andwho tolerated treat-
ment, were eligible to receive bosentan therapy in the OLE phase. As treatment was still
blinded at the start of the OLE phase all patients who continued in the study received an
initial dose of bosentan 62.5 mg twice daily for 4 weeks followed by up-titration to the
125 mg twice-daily target dose. The dose could remain at, or be down-titrated to, the ini-
tial dose at any time for reasons of intolerability,with subsequent up-titration to the target
dose.
2.3. Study assessments
All non-invasive efﬁcacy assessments conducted in the double-blind phase continued
in the OLE phase. These exploratory efﬁcacy outcomes (6-minute walk distance [6MWD],
Borg dyspnea index and WHO FC) were assessed during the OLE at 6-month clinic visits
and at the end of the extension phase or premature withdrawal visit. Only adverse events
(AEs) which led to premature discontinuation of bosentan, or a fatal outcome, were re-
corded during the OLE phase, while serious AEs (SAEs) were recorded up to 28 days
post treatment.Monthly liver function tests (which included alanine and aspartate amino-
transferases [ALT/AST]), quarterly hemoglobin tests, and monthly pregnancy tests in
women of childbearing age were conducted throughout the OLE phase. Complete labora-
tory tests were performed at the end of the OLE phase or at premature withdrawal visit.
Concomitant PAH medications were continuously monitored throughout the EARLY
study. In all randomizedpatients PAHworsening events (death [all causes], initiation of in-
travenous (iv) or subcutaneous (sc) prostanoids, atrial septostomy and lung transplanta-
tion), and use of other PAH medications were recorded annually until the end of study,
independently from bosentan treatment duration.2.4. Data analysis of the bosentan-treated population
The bosentan-treated population comprised all patients who received ≥1 dose of
bosentan during the double-blind or OLE phases. Demographics, disease and clinical char-
acteristics at baseline, bosentan exposure, exploratory efﬁcacy outcomes, and safety pa-
rameters were described or evaluated. The analysis of PAH worsening and survival
included all events irrespective ofwhether or not they occurredduring the bosentan treat-
ment period. Baselinewas deﬁned as the last assessment before bosentan treatment. That
is, for patients receiving placebo during the double-blind phase, baseline values were ob-
tained at the last assessment before receiving drug in the open-label phase, and for those
patients initially randomized to bosentan, baseline was the last assessment before the
double-blind phase. There was no imputation for missing data, except for missing or in-
complete dates in AE and concomitant medication data. Unless otherwise stated, data
were summarized descriptively: mean ± standard deviation (SD) (and if informative
also as median [range]) for quantitative variables; frequency and proportions for categor-
ical variables.
For the exploratory efﬁcacy outcomes, change from baseline at study end, and at
6-month intervals up to Month 36 (retrospectively chosen as N75% patients had data
available at this time point), in patients for whom data were available at each speciﬁc
time point, were reported for 6MWD and Borg dyspnea index. Changes in WHO FC
from baseline were reported at study end. The proportions of patients who improved
to a lower FC or deteriorated to a higher FC at the end of treatment were also provided
together with 95% conﬁdence intervals (CI).
Safety data are presented for patients who had ≥1 AE and events per 100 patient-
years are provided. Elevations of ALT/AST N 3 × upper limit of normal (ULN) and marked
decreases in hemoglobin ≤ 10 g/dL during the bosentan-treatment period are described.
Time to ﬁrst ALT/AST elevation during the same treatment period with event rate
corrected to account for individual exposure times was determined by Kaplan–Meier
analysis.
For PAH worsening and survival, Kaplan–Meier analysis (estimates reported as per-
centages and 95% CI) was used to estimate time to PAH worsening and its separate com-
ponents. A post-hoc comparison of the patients on monotherapy at the start of the EARLY
studywho remained onmonotherapywith thosewhohadmoved on to combination ther-
apy at 4 yearswas performed for patientswho had a) died, b)were known to be alive and
c)who had been censored. Time to deathwas further estimated by Kaplan–Meier analysis
according to PAH etiology, as was time to initiation of other PAH-targeted drugs (oral
phosphodiesterase type 5 inhibitors and/or oral/inhaled prostanoids).
2.5. Cox analysis on the all-randomized population
In order to determine factors prognostic of survival, Cox regression analyseswere con-
ducted on the all-randomized populationwhich included all randomized patients, wheth-
er they received study medication or not. Univariate (signiﬁcance set at p b 0.1 cut-off)
and multivariate (backward selection set at p b 0.1 cut-off, including all variables having
a p-value b 0.1 in the univariate analysis) Cox analyses were employed.
3. Results
3.1. Patient disposition
One hundred and eighty-ﬁve patients were randomized in the
double-blind phase of EARLY (Fig. 1); 92 to placebo and 93 to bosentan
and constituted the all-randomized population. Of these, 80/92 who
were randomized to placebo and 77/93 randomized to bosentan en-
tered the OLE phase. In total, 173 patients received≥1 dose of bosentan
during the double-blind or OLE phase and constituted the bosentan-
treated population.
3.2. Bosentan-treated population
3.2.1. Baseline characteristics
Baseline patient demographics aswell as disease and clinical charac-
teristics for the all-randomized population have been previously report-
ed [8]. Table 1 reports baseline patient demographics and disease and
clinical characteristics for the bosentan-treated population. Patients in
the OLE phase of EARLY had a similarly mild clinical proﬁle as the
double-blind cohort, with over 90% being classiﬁed as WHO FC II, a
high 6MWD and a low Borg dyspnea index. However, high baseline
PAP, PVR, and right atrial pressure show that the patientswere hemody-
namically compromised.
3.2.2. Bosentan exposure
Due to the study design, exposure to bosentanwas variable. Overall,
73.3% of patients received bosentan for at least 3 years and 61.6% for at
Fig. 1. Patient disposition. Patient ﬂow and disposition in the randomized, double-blind study and open-label extension. *Patients comprising the bosentan-treated population, n = 173.
AEs = adverse events; DB = double-blind; OL = open-label. †Administrative/other reasons included protocol violation or non-compliance, withdrawal of consent, personal reasons,
investigator's decision, switch to commercial drug, switch to another study.
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bosentan was 43.3 (SD 21.5) months and median (range) exposure
was 51.4 (0.1–72.8)months (n = 172; 1 patientwas lost to follow-up).
3.2.3. Exploratory efﬁcacy outcomes
A total of 154 patients had baseline and at least one post-baseline as-
sessment for 6MWD and Borg dyspnea index. Mean change from base-
line to end of treatment in 6MWD was −3.7 m (95% CI −17.0, 9.5).
Mean changes from baseline to 6-month intervals up to Month 36 are
shown in Fig. 2 for patients who had an assessment at each point. On
the Borg dyspnea index upon exercise, there was a minimal change
from baseline to end of treatment (mean score 0.30 [95% CI −0.02,
0.62]). Similarly, mean changes from baseline to 6 monthly intervals
up to Month 36 were minimal.
Of the 158 patients who had available post-baseline WHO FC data,
154 (97.5%) were classiﬁed asWHOFC I or II at baseline. At end of treat-
ment, the majority of patients (n = 123; 77.8%) were still in WHO FC I
or II, with 27 (17.1%) inWHO FC III, and 8 (5.1%) inWHOFC IV (Table 2).
Overall, 18.4% (95% CI 12.7, 25.3) of patients had improved and 22.8%
(95% CI 16.5, 30.1) had deteriorated.
3.2.4. Safety
Thirty-ﬁve patients (20.2%) had an AE that led to bosentan discon-
tinuation, which equates to 5.6 events per 100 patient-years. All AEs
leading to bosentan discontinuation are listed in supplementary
Table S2.
For seven patients (4%)worsening of PHwas recorded as anAE lead-
ing to discontinuation, in the double-blind phase (one patient) or open-
label phase (six patients). However, the most common AE that led to
bosentan discontinuation was coded as an abnormal liver function test
in 12 patients. One further patient who was speciﬁed as having in-
creases in ALT and AST also discontinued bosentan.
There were three additional patients with ALT/AST elevations N3×
ULN but whose reason for discontinuation from bosentan was reported
as hepatitis and hepatitis C (one patient), toxic hepatitis (one patient)
and autoimmune hepatitis (one patient). While in the double-blind
study period the patient with hepatitis C ﬁrst experienced iatrogenic
hepatitis, considered an adverse drug reaction to bosentan, whichimproved following drug discontinuation. This was followed by hepati-
tis C, with eventual recovery of aminotransferase levels to normal base-
line values. The events were judged by the investigator to be serious,
severe and related to bosentan treatment, resolving with sequalae.
For the patient with toxic hepatitis the event occurred during the
open label phase of EARLY. Bosentan was temporarily interrupted
for 23 days and restarted at the 62.5 mg dose but permanently
discontinued 9 days later. The event resolved without sequelae. The in-
vestigator considered this non-serious event to bemoderate in intensity
and related to bosentan treatment. For the patient with autoimmune
hepatitis, the condition had been diagnosed to be pre-existing and re-
current. In this patient the elevated liver enzymes (N8 × ULN)were un-
resolved but had, prior to bosentan discontinuation, been treated
without tolerability issues for 3.5 years. The elevations in liver enzymes
were considered by the investigator not to be related to bosentan treat-
ment. At the last safety follow-up before study end her clinical condition
improved and liver function tests were being conducted twice weekly.
Over the 5-year duration of the study, 29/173 (16.8%) patients expe-
rienced elevations in ALT and/or AST N 3 × ULN,with 14patients (8.1%)
having elevations N8 × ULN. The majority of the ALT and/or AST eleva-
tions occurred by Year 1, with all 20 events actually occurring in theﬁrst
6 months, giving a crude event rate of 11.6% at Month 6. The number of
additional events by Years 2, 3, 4 and 5 were 5, 2, 1 and 1 respectively.
The Kaplan–Meier estimate of time to AST/ALT elevation which
corrected for the shorter exposure time of bosentan for some patients
provides event rates of 12.0% at Month 6 (which is the same as at Year
1) and 18.6% at Year 5 (Fig. 3). The Kaplan–Meier curve clearly shows
that the majority of these cases occurred within the ﬁrst 6 months of
bosentan treatment, with few additional patients experiencing liver en-
zyme elevations—after 6 months.
All but one case of elevated liver enzymes, as described above in the
patient with pre-existing, recurrent autoimmune hepatitis, resolved
after either a decrease in the bosentan dose, continued treatment, or
after treatment discontinuation.
A hemoglobin concentration of ≤10 g/dL was found in 26 (15.0%)
patients, only one of whom had a pre-treatment baseline value of
≤10 g/dL. No patient discontinued bosentan due to anemia, two pa-
tients required dose reduction, and transfusionwas reported in six cases.
Table 2
Change in WHO functional class from baseline to end of treatment (bosentan-treated
population).
n Baseline End of treatment period
n I
n (%)
II
n (%)
III
n (%)
IV
n (%)
158a I 5 3 (1.9%) 2 (1.3%) – –
II 149 27 (17.1%) 89 (56.3%) 26 (16.5%) 7(4.4%)
III 4 1 (0.6%) 1 (0.6%) 1 (0.6%) 1 (0.6%)
IV 0 – – – –
a 158 patients who had post-baseline WHO functional class data were included in this
analysis. Data are missing from 15 patients; 2 died and 13 patients did not have valid
post-baseline data.
Table 1
Patient demographics and baseline characteristics (bosentan-treated population).
Characteristic Bosentan-treated population
(n = 173)
Sex, n (%)
Female 120 (69.4)
Age, yrs 45.0 ± 17.6
Weight, kg 68.5 ± 16.3
Race
White 148 (85.5%)
Asian 11 (6.4%)
African descent 5 (2.9%)
Hispanic 1 (0.6%)
Other 8 (4.6%)
Time from diagnosis, yrs 3.4 ± 5.9
Etiology
Idiopathic/heritable 106 (61.3%)
Congenital heart diseasea 31 (17.9%)
Connective tissue disease/auto-
immune disease 29 (16.8%)
Human immunodeﬁciency virus 7 (4.0%)
Concomitant treatments
Oral anticoagulants 98 (56.6%)
Platelet aggregation inhibitors excluding heparinb 14 (8.1%)
Heparin 12 (6.9%)
Calcium channel blockers 58 (33.5%)
Sildenaﬁl 29 (16.8%)
6-minute walk distance, m 435.8 ± 93.5
Borg dyspnea index 3.31 ± 2.09
WHO functional class
I 6 (3.5%)
II 160 (92.5%)
III 7 (4.0%)
Hemodynamic parameters
Mean pulmonary arterial pressure, mmHg 53.1 (8.3)c
Mean right atrial pressure, mmHg 7.5 (4.7)c
Pulmonary capillary wedge pressure, mmHg 9.4 (4.2)d
Cardiac output, L min−1 4.6 (1.5)e
Cardiac index, L min−1 · m−2 2.7 (0.8)e
Pulmonary vascular resistancef, dyn s cm−5 853.0 (505.2)
a n = 170. Unless otherwise stated data are presented as mean (standard deviation).
b Platelet aggregation inhibitor was acetylsalicylic acid.
c n = 172.
d n = 165.
e n = 169.
f When pulmonary capillary wedge pressure was not determined, it was set to 0 in the
calculation of pulmonary vascular resistance.
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treated-population; 21 deaths had occurred within the 28-day period
after bosentan discontinuation and nine had occurred more thanFig. 2. 6-Minute walk distance. Change in 6-minute walk distance from baseline at 6
monthly intervals up toMonth 36 in the bosentan-treated population. Data are presented
asmeans and standard errors of themean. PAH=pulmonary arterial hypertension; PDE5
= phosphodiesterase type 5; iv = intravenous; sc = subcutaneous.28 days after bosentan discontinuation. Of the patientswhodied during
the bosentan treatment period or within 28 days after discontinuation,
progression of PAH (four patients), pneumonia and sudden death (three
patients each) were the most frequent causes of death. The treating
physician judged death to be related to study medication in two
cases (convulsions/vasculitis/worsened PAH, and antiphospholipid
syndrome/sudden death/systemic lupus erythematosus).3.2.5. PAH worsening and survival
The estimated proportion of patients who remained free of PAH
worsening (event-free survival) at 1, 2, 3, and 4 years were 96.5%,
90.7%, 87.8%, and 79.5%, respectively (Fig. 4A). PAH worsening events,
which occurred as ﬁrst events, were death (n = 25) and initiation of
iv or sc prostanoids (n = 18). Two patients underwent lung transplan-
tation, both of whom ﬁrst received iv or sc prostanoids. Survival esti-
mates at 1, 2, 3, and 4 years were 97.1%, 92.4%, 90.1%, and 84.8%,
respectively (Fig. 4B). Patients with PAH-CTD had poorer survival than
those with idiopathic/heritable PAH or PAH-CHD (Fig. 4C).
It was estimated that after 4 years, 7.6% of patients had received iv or
sc prostanoid therapy (Fig. 4D) and 29.6% of patients had received other
PAH-targeted drugs, namely phosphodiesterase type 5 inhibitors
(sildenaﬁl or tadalaﬁl) and/or oral/inhaled prostanoids (Fig. 5). At
4 years, among the 144 patients who had started bosentan as a mono-
therapy (i.e. excluding the 29 already on sildenaﬁl at baseline, see
Table 1), 21 were known to have died (15 remained on monotherapy,
six had received combination therapy) and four were lost to follow-up
and censored. Of the 119 patients known to be alive at 4 years, 75Fig. 3. Liver enzymes. Kaplan–Meier estimates of time to alanine and aspartate amino-
transferase elevations in patients receiving bosentan in the bosentan-treated population.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = conﬁdence
intervals; NA = not applicable.
Fig. 4. Time to pulmonary arterial hypertension worsening, overall and by its components. Kaplan–Meier estimates of time to A) pulmonary arterial hypertension worsening; B) death
(all causes) all patients; C) death (all causes) by PAH etiology, andD) intravenous/subcutaneous prostanoid initiation in the bosentan-treated population. Pulmonary arterial hypertension
(PAH) worsening was deﬁned as ﬁrst occurrence to death (all-causes), initiation of intravenous/or subcutaneous (iv/sc) prostanoids, atrial septostomy or lung transplantation. Causes of
PAH worsening were death (n = 25; 58.1% and initiation of an iv/sc prostanoid (n = 18, 41.9%). CI = conﬁdence intervals; hPAH= heritable pulmonary arterial hypertension; iPAH=
idiopathic pulmonary arterial hypertension; NA=not applicable; PAH-CHD=pulmonary arterial hypertension associatedwith congenital heart disease; PAH-CTD=pulmonary arterial
hypertension associated with connective tissue disease.
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All four censored patients were on monotherapy at time of censoring.
3.2.6. All-randomized population—prognostic factors of survival
The univariate Cox analysis conducted in the all-randomized popu-
lation, forwhich therewere 35 deaths in this population, showed signif-
icant prognostic factors for a high risk of death were time since PAH
diagnosis of up to 16 months, 6MWD ≤ 437 m, mixed venous oxygen
saturation ≤68%, high levels of N-terminal pro hormone of brain natri-
uretic peptide (NT-proBNP) and a diagnosis of PAH-CTD (Table 3).With
the exception of time since PAH diagnosis, all these factors were con-
ﬁrmed as signiﬁcant in the multivariate analysis (Table 3).4. Discussion
The exposure to bosentan in EARLY exceeds that ofmany other stud-
ies. As such, EARLY provides valuable information on the long-term
safety, in particular liver safety, of bosentan in patients with PAH. The
4-year data from this study also underscore the fact that patients with
WHO FC II PAH have a severe and often fatally progressive disease.
PAH worsening occurred at a rate of approximately 5% annually and
mortality, estimated at 15% over 4 years, remains substantial. An impor-
tant ﬁnding of this study was the identiﬁcation of a priori factors
that portend a poor outcome in WHO FC II patients treated with
monotherapy. This could be useful in identifying a high-risk incident
Fig. 5. Time to other drug initiation. Kaplan–Meier estimate of time to other pulmonary arte-
rial hypertension-targeted therapy (phosphodiesterase type 5 inhibitors and oral/inhaled
prostanoids) in the bosentan-treated population. The number of patients for whom phos-
phodiesterase type 5 inhibitors were added was 48 and the number of patients for whom
oral/inhaled prostanoidswere addedwas13. CI=conﬁdence intervals; NA=not applicable.
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therapy. Lastly, the use of standard efﬁcacy measures in EARLY can
also provide some indication of the symptomatic efﬁcacy of bosentan
over the long-term but these data need to be interpreted with caution.
4.1. Safety
Information on elevations in liver enzymes was of primary impor-
tance in the EARLY study given the long period of bosentan exposure
in this study of up to 5 years. Thus we report all elevations of AST
and/or ALT regardless of whether they led to bosentan discontinuation.
The proportion of patients with AST and/or ALT elevations (irrespective
of whether they led to bosentan discontinuation or not) in EARLY was
16.8% (crude rate) or 18.6% by Kaplan–Meier estimate. Given that
most patients were treated for at least 4 years, this rate is not unexpect-
ed and is similar to that of open-label bosentan studies of up to 3 years
exposure [9]. Consistent with these previous ﬁndings [9] most of theTable 3
Signiﬁcant prognostic factors for a low and high risk of death in patients with WHO functiona
randomized population).
Univariate analyses
(n = 185)
Baseline parameter Hazard ratio 95% CI
Time since PAH diagnosis N 16 months (n = 183) 0.47 0.22–1
6MWD (N437 m) (n = 185) 0.44 0.22–0
Mixed venous oxygen saturation N 68% (n = 167) 0.26 0.11–0
NT-proBNP (10-fold increase)c (n = 158) 2.71 1.39–5
Etiology (n = 185)
–CHD vs iPAH/hPAH-HIV 0.32 0.07–1
–CTD vs iPAH/hPAH-HIV 2.33 1.15–4
–CTD vs iPAH/hPAH–HIV–CHD – –
Variables included in the univariate analyses: Time from diagnosis (≤16 months, N16 month
Nmedian); NT-proBNP (log-transformed); cardiac index (≤median, Nmedian); pulmonary v
Nmedian); sex (male, female); age (≤median, Nmedian); etiology (3 classes: iPAH/hPAH-HIV
combination therapy (sildenaﬁl) therapy at baseline.
CHD = congenital heart disease; CTD = connective tissue disease, HIV = human immunode
proBNP = N-terminal pro hormone of brain natriuretic peptide; 6MWD= 6-minute walk dist
a Multivariate analysis was conducted on patients without missing data for the variables ret
b Dropped from the multivariate analysis during backward selection.
c Risk of a patient with an NT-proBNP level 10-fold greater than another patient who otherw
d Global test for inﬂuence of etiology.
e Since (CHD vs iPAH/hPAH-HIV) was not selected by univariate analyses, etiology was reduincreases in AST and/or ALT associated with bosentan occurred during
the ﬁrst 6 months of treatment. The crude rate estimate at Month 6
of 11.6% and the Kaplan–Meier estimate of 12.0% are similar to the
6-month estimate of 11.3% reported in the Tracleer® (bosentan) Sum-
mary of Product Characteristics [10].While it is more likely that later in-
creases in liver enzymes are associated with the disease or other
background factors or concomitant medications given as patients dete-
riorate, bosentan-related increases cannot be excluded from occurring
later on during the course of therapy. These data highlight that monthly
blood tests to monitor liver enzymes should be conducted the entire
time a patient is treated with bosentan. Treatment discontinuation,
dose reduction or continued treatment coupled with regular assess-
ment should be employed in cases of liver enzyme abnormalities. As ev-
idenced in this study, most cases of elevated liver enzymes are resolved
after deployment of one of these strategies.
Of the 29 patients with elevated liver enzymes of N3 × ULN, 16
discontinued bosentan treatment. For 13 of these patients, the eleva-
tions were asymptomatic and recorded as either an AE of abnormal
liver enzymes (in 12 patients) or speciﬁed as an AE of increased ALT
and AST. Three patients had elevated aminotransferases with a clinical
presentation of hepatitis, which was recorded as the AE leading to dis-
continuation. In two of these cases the investigator considered the hep-
atitis to be drug related, however as liver biopsywas not performed it is
not possible to conﬁrm if this was the case.
Seven patients discontinued bosentan due toworsening of their pul-
monary hypertension, one in the double-blind phase of the study and
six in the open-label phase. In the double-blind phase the protocol spec-
iﬁed that patients who worsened should discontinue treatment. While
in the open-label phase patients could continue bosentan treatment if
another PAH-targeted therapy was added, combination therapy was
not common clinical practice during some of the time the trial was
being conducted.
Twenty-one patients died while taking bosentan, or within 28 days
after cessation, and most deaths were due to PAH or conditions that
would be expected in a population of chronically ill patients. In two
cases deathwas linkedby the treatingphysicians to bosentan (see above).
4.2. Estimates of PAH worsening and survival, and prognostic factors
for survival
As data on PAH worsening and vital status were collected for all
bosentan-treated patients, independently of treatment duration,l class II pulmonary arterial hypertension (univariate and multivariate analyses in the all-
Multivariate analysis
(n = 142a)
p Hazard ratio 95% CI p
.00 0.0493 – – –b
.90 0.0241 0.47 0.21–1.08 0.0739
.61 0.0019 0.26 0.09–0.72 0.0093
.28 0.0034 2.28 0.99–5.26 0.0541
0.0090d
.36 0.1234
.75 0.0192
– 4.28 1.81–10.09 0.0009e
s); randomization group at start of double-blind (placebo, bosentan); 6MWD (≤median,
ascular resistance (≤ median, N median); mixed venous oxygen saturation (≤median,
, CHD, CTD); mean blood pressure (from vital signs (≤median, Nmedian); monotherapy/
ﬁciency virus; iPAH/hPAH = idiopathic/heritable pulmonary arterial hypertension; NT-
ance.
ained (p-value b 0.1 in univariate analyses).
ise has the same characteristics.
ced to CTD vs iPAH/hPAH-HIV-CHD.
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FC II PAH population. At 4 years, event-free survival and survival were
approximately 80% and 85%. These data conﬁrm that survival has im-
proved in the era of PAH-targeted therapy versus historical data from
the pre-drug era [11]. However, a death rate of 15% over 4 years in a
mildly symptomatic PAH patient population still shows how further re-
search into new treatments, more effective treatment strategies, and
understanding the disease are still required.
Data collection on vital status for all randomized patients also
enabled a Cox analysis to be conducted to identify factors that were pre-
dictive of death.We identiﬁed 6MWD of 437 m or less, a PAH diagnosis
of 16 months or less, a mixed venous oxygen saturation of 68% or less,
high NT-proBNP levels, and PAH-CTD as factors prognostic of a high
risk of death in WHO FC II patients. Such information can alert physi-
cians to pay particular attention to patientswith risk factors and employ
modiﬁed treatment strategies such asmore regular assessment ormore
aggressive treatment including up-front combination therapy, although
this is not currently supported by randomized clinical trial evidence.
Similar high risk factors have also been identiﬁed in other studies. In
the Sildenaﬁl Use in Pulmonary Hypertension (SUPER)-2 trial, Cox re-
gression analysis showed that for patients who had a 6MWD of
b325 m at baseline in SUPER-1, deterioration in 6MWD during the
ﬁrst 12 weeks of sildenaﬁl treatment was associated with poor survival
(hazard ratio 0.241). The association was weaker between change in
6MWD and survival in patients with a 6MWD ≥ 325 m at baseline
[12]. High 6MWD (≥440 m) is also associated with a low score on
The Registry to EValuate Early And Long-term pulmonary arterial hy-
pertension diseasemanagement (REVEAL) risk score calculator [13]. Al-
though time since diagnosis of more than 16 months was no longer
predictive of better survival in the multivariate analysis, it should be
noted that the multivariate analysis was underpowered compared
with the univariate analysis since patients who had missing data for
any the parameters included in themultivariate analysiswere excluded.
B-type natriuretic peptide (BNP) and NT-proBNP are biomarkers of
heart failure and high plasma levels have consistently been reported
as predictors of mortality [14–16]. NT-proBNP levels N 1400 pg/mL
and N1800 pg/mL, respectively, have been shown to be predictive of
worse 3-year outcomes in patients with severe PAH [7,16] and prognos-
tic analysis fromREVEAL shows BNP levels N 180 pg/mL are signiﬁcant-
ly associated with death [14]. High BNP levels are part of the risk score
calculator from REVEAL [13].
That the Cox regression analysis identiﬁed PAH-CTD as a high risk is
congruent with the Kaplan–Meier survival analysis by etiology in this
study and in other studies, such as the French PAH Registry [17],
which showed PAH-CTD patients to have poorer survival than those
with iPAH or PAH-CHD. REVEAL conﬁrms a signiﬁcantly lower survival
rate at 1 year in PAH-CTD vs iPAH, 86% vs 93%; p b 0.0001 [18].
4.3. Exploratory efﬁcacy outcomes of bosentan treatment
Over the course of the bosentan treatment period (median 51.4 -
months) exercise capacity was largelymaintained in themajority of pa-
tients. However, care must be taken when interpreting the 6WMD and
Borg dyspnea index data as the changes are a populationmean and thus
include data from responders and non-responders aswell as patients on
combination therapy or bosentan monotherapy. Other PAH-targeted
therapies, namely phosphodiesterase type 5 inhibitors and oral or
inhaled prostanoids, were initiated gradually over time and, after
4 years, 30% of patients were receiving combination therapy. The ob-
served less than expected number of patients on combination therapy
is a reﬂection of the EARLY protocol, which allowed for new drugs
only to be added if patients deteriorated. Treating and maintaining pa-
tients in WHO FC II with monotherapy, if possible, and combination
therapy where required, is recommended as a key treatment goal [19].
In this study, 78% of the patients remained in WHO FC II or improved
to WHO FC I during a 4-year observation period.5. Study limitations and strengths
One of the biggest limitations of this study is a lack of comparator.
Ethical considerations prohibited the inclusion of a long-term placebo
arm. A second limitation is the fact that some patients received
additional therapy, either at baseline or during follow-up, and so the
data are not from a monotherapy study. Moreover, as few patients
(n = 29)were on sildenaﬁl at baseline it is not possible to draw conclu-
sions with regards to combination therapy. A further limitation of this
studywas that PAHworsening eventswere not adjudicated and only in-
cluded endpoints that could reliably and realistically be collected over
such a long-term study, eg initiation of iv or sc prostanoids and death.
Therefore, data on disease worsening cannot be directly compared
with similar data from other studies which may have included disease
progression measures such as deterioration in 6MWD.
This data set is the only comprehensive one to report long-term re-
sults, with themajority of patients being treated for at least 4 years, in a
primarily mildly symptomatic PAH population (97.5% in WHO FC I/II at
baseline). Despite some larger OLE studies having a relatively high pro-
portion of patients in WHO FC I/II, [12,20] in-depth analyses of this pa-
tient sub-population examining factors such as survival and clinical
worsening have not been published. Patients were followed up for the
entire duration of the study, irrespective of whether they remained on
bosentan for events related to PAHworsening. Thus the analysis of sur-
vival and PAH worsening was akin to the intent-to-treat principle, pro-
viding robust data for these long-term results. Data from the EARLY
study provide relevant clinical information on aWHO FC II PAH patient
population treated with an advanced PAH therapy with regards to dis-
ease progression, patient survival, and factors associated with survival.
6. Conclusion
The tolerability and safety of an extended period of bosentan expo-
sure in this patient population was in line with its known safety proﬁle.
PAH patients in WHO FC II had a 4-year survival rate of approximately
85%. A low 6MWD, a low mixed venous oxygen saturation, a high NT-
proBNP level, and PAH-CTDwere associatedwith a greater risk of death.
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